LIVN

LIVN is executing a 'High-Conviction Price Discovery' phase, breaking out to 52-week highs driven by a structural valuation reset rather than speculative hype. The primary engine is a massive 48% increase in Medicare (CMS) reimbursement for its VNS epilepsy therapy (effective Jan 1), which KeyBanc validated last week with a Street-high $81 target. This idiosyncratic strength perfectly aligns with the 'Neutral' macro regime, as capital rotates out of high-beta 'Rocket Ships' and into high-quality healthcare names with visible profitability inflections.